CVRx Inc
NASDAQ:CVRX
Gross Margin
CVRx Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
C
|
CVRx Inc
NASDAQ:CVRX
|
317.3m USD |
84%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
228B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
176.8B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
147.9B USD |
68%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
142B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.6B USD |
66%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
65.6B USD |
45%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.1B EUR |
38%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
42.3B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
286.9B CNY |
64%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
36.4B USD |
42%
|
CVRx Inc
Glance View
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on CVRx Inc's most recent financial statements, the company has Gross Margin of 83.8%.
You don't have any saved screeners yet